CD274 and gastric cancer: In the EU, pembrolizumab in combination with CT is indicated in patients with GC/GEJC whose tumors express PD-L1 with a combined positive score (CPS) of ≥ 1, and nivolumab in combination with CT is indicated in patients whose tumors express PD-L1 with a CPS of ≥ 5 [18, 19].